TC-99M GLUCARATE FOR CHEST PAIN TRIAGE IN EMERGENCY ROOM

TC-99M 葡萄糖酸盐用于急诊室胸痛分诊

• 批准号: 2867227
• 负责人: Koon Y Pak
• 金额: $ 13.46万
• 依托单位: MOLECULAR TARGETING TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2001-01-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2867227
• 关键词: diagnosis design /evaluation; drug design /synthesis /production; human subject; myocardial infarction; pain; pharmacokinetics; radiation dosage; radiodiagnosis; radiopharmacology; sugar acids; technetium; thoracic radiography; thorax

Currently, approximately 6.0 million patients enter emergency departments each year complaining of chest pain. Approximately, 500,000 patients are immediately dosed as having acute myocardial infarction (MI) based on an ECO, and an additional 500,000 are ultimately diagnosed as having acute MI based on tests based on cardiac enzymes. Approximately l.5 million are ultimately diagnosed with unstable angina and undergo cardiac treatment and monitoring. Unfortunately, approximately 35,000 of these 3.5 million patients are sent home with a missed acute MI diagnosis, and 6,000 of these MI patients die within 48 hours. In addition, 2.1 million of these 3.5 million patients are diagnosed after extensive evaluation and hospital stays. National statistics indicate that approximately $4.0 billion of unnecessary medical costs are incurred annually on these equivocal MI patients. Time is a critical factor in the treatment of acute MI patients. The purpose of the Phase I research is to evaluate the safety, pharmacokinetics, and radiation dosimetry of Tc-99m glucarate and that of Phase ll is to establish the usefulness of this reagent in the emergency department to enable accurate triage of patients with acute MI form chest pain of non- cardiac origin. PROPOSED COMMERCIAL APPLICATION: Tc-99m glucarate can be used to identify acute myocardial infarction patients. The establishment of such a procedure in emergency room should provide a fast rule-in and rule-out of patients with chest-pain and should conserve scarce healthcare resources.

目前，每年大约有6000万患者进入急诊室，抱怨胸痛。大约有500,000例基于ECO的急性心肌梗死（MI）的患者，最终被诊断为基于基于心脏酶的测试的急性MI。大约150万卢比最终被诊断出患有不稳定的心绞痛并接受心脏治疗和监测。不幸的是，在这350万患者中，大约有35,000名因急性MI诊断而被送回家，其中6,000名MI患者在48小时内死亡。此外，在经过广泛评估和住院后，诊断出350万患者中有210万人被诊断出。国家统计数据表明，这些模棱两可的MI患者每年发生约40亿美元的不必要的医疗费用。时间是治疗急性MI患者的关键因素。第一阶段研究的目的是评估TC-99M葡萄糖酸盐的安全性，药代动力学和辐射剂量测定法，而LL期的安全性是为了确定该试剂在急诊室中的有用性，以使非心脏起源的急性MI胸痛患者精确分类。拟议的商业应用：TC-99M葡萄糖酸盐可用于鉴定急性心肌梗塞患者。在急诊室建立这样的程序应提供胸痛的患者的快速规则和排除，并应节省稀缺的医疗保健资源。